Cel-Sci May Be in for a Bumpy Ride This Week 34 comments
an article to
-
Font Size:
-
Print
- TweetThis
It looks like the writing staff at BioMedReports.com, most notably M. E. Garza, must be getting under Adam Feuerstein's skin because he's decided to enact a personal vendetta with the website. The thing is, it makes Adam and his puppetmasters at the The Street.com looks pretty bad when other sites post facts about a company and its stock, and then form opinions based on those facts. Since BioMedReports was doing just that, Adam decided to bash that website along with a bash on Cel-Sci (CVM).
It's my opinion that the Adam bash parade is starting to lose steam, in my opinion, in the same way that the 'cry wolf' ended up losing steam for 'The Boy Who Cried Wolf'. Any positive news from CVM this week will negate any downside influence that Adam F. had on the stock.
The only ones that follow the Street.com any more are the big boys that count on them to bash or pump whenever they need a puppet to do their bidding - which does not include looking out for the little guy. When Feuerstein tells a story, he only tells you part of the story.
Regardless of the Adam F. controversy, there's quite a bit of news pending during the fourth quarter - including Multikine news, the opening of the Baltimore facility and LEAPS - that could influence the price of this stock. It could get bumpy this week - if there is no news released I wouldn't be surprised to see the stock dip down to below the $1.50 level one more time.
Disclosure: VFC is long CVM.
Related Articles
|
-
The Seeking Alpha 100
See allThe top 100 stock
market authors
selected for publication
Seeking Alpha 100 » -
Fastest Climbers
Authors with the largestSee all
increase in followers
in the last 7 days
Fastest Climbers » -
Top Commenters
Top commenters,See all
as ranked by their peers
Top Commenters » -
Top Instabloggers
The 100 most activeSee all
Instabloggers.
Top Instabloggers » -
Top StockTalkers
TopSee all
StockTalkers.
Top StockTalkers »
Roy
I'm in for the long run.
As for CVM, I have been in and out of it many times and will continue to actively trade it.
I caught AF's piece on CVM and immediately began wondering about his validity - bashing isn't investment advice. I'm also no fan of Cramer. Sounds a lot like the boys from Motley Fool when they miss a deal and poo-poo it when it takes off (see SCLN and maybe CVM?)).
Rock on, Biomed!
Adam F might be biased and have his own agenda,
Biomed report might be biased and have their own agenda,
and you VFC stock of course (per your disclosure) biased and have your own agenda too.
so the best thing for every reader is to do their own due dilligence,
and cross examine all the posting from everybody and combine
them with your own experience and gut instinct.
The truth usually lie in the middle.
Still, I enjoy reading Adam F article more because, he do provide his article with some data from previous trial which off course support his bearish argument.
while BioMed report (especially Garza), most of the time only present story about their interview with the CEO.
Adam F is not perfect, he was wrong on DNDN and VNDA and many more,
but I don't think everybody is perfect.
BioMed Reports sure had and will continue to make mistake,
Motley fools too,
I am too,
VFC stockhouse too...
too suggest that Adam F is playing this for the hedge funds is ok if you can prove it.
and if you can prove it, Adam F could end up in lawsuit.
so please, if you have prove, then you should press charges against Adam F, but if you can not prove it, then please stop.
All this penny biotech stock madness start with DNDN and then VNDA.
so most of the time people are winning big on biotech stock because they are in the right upward momentum for this penny biotech stock, and not because they pick the right stock.
so, a lot of people can now claim how good they are by showing their huge portfolio gain on penny biotech stock.
but that do not mean that biotech company will eventually succeed with their trial and able to get their drug approved by FDA !
so for all the blogger and poster here,
rather than spending most of your time posting high price target for your own stock,
why don't you guys start posting the DATA from previous clinical trial of that company that will be self explanatory as the reason why you are bullish on this stock.
Biotech is all about DATA ! and when you are debating with DATA,
it will be clear, who is right and who is wrong.
and when I talk about DATA, I don't mean just talking about DATA from the company glossy press release,
but the DATA from their SEC filing or competitor previous clinical trial data and other more independent data !
if you guys really want to help the "little guy" then you guys should help them so they can understand what the DATA mean,
and not just posting some bullish price target or some company interview material !!!
That is NOT helping the little guy.
Most of the post from Garza and some from you VFC stockhouse,
mostly point out the Bullish reason,
but fail or rarely mention the RISK on that company trial or other risk.
You got to write all the positive and negative things about the stock,if you really want to help the little guy...
You got to be balance, even though you own/long on that company stock.
when you do that, your credibility become better,
and when you finally right about the company,
only then you can say proudly :
I TOLD YA !
On Oct 05 12:41 PM dreamdivers wrote:
> "The guys at BioMed actively seek out sources"??? You must be joking.
> The only sources they ever refer to for companies like CVM are the
> CEO, "anonymous insiders", "a source close to the company", and other
> such dubious people. They do almost no due diligence, never ask any
> hard questions, and never seem to follow up. Why do you think these
> companies go to Garza to begin with? Because they know they'll get
> a puff piece with no hard questions asked. Look, if you want to trade
> these stocks based on run ups on hype from the like of Garza, that's
> fine and good luck. But to suggest that his type of reporting is
> truly deep and objective, therefore deserves any real credibility
> is laughable.
I wouldn't classify the article by Dr. Romanus as a "Booster" piece.
It's a technical explanation in layman's terms as to what the swine flu is and how CVM plans to use LEAPS to treat it. This is not new information and LEAPS technology already exists for other diseases.
For all practical purposes, the article in question could have been pulled out of Wikipedia.
Anyway, another buying opportunity has been created and DD is king.
CVM will finish the year <$1, of this I have ZERO doubt.
LEAPS! What a joke, They should call it "Leap of faith" to milk investors.
You, my friend, are a tool.
On Oct 06 11:52 AM Goosie69 wrote:
> I wonder what this www.thestreet.com/stor...
> will lead to?
A couple of points: Biotechs_Maven, some good points in there, but I do think that it is OK to speculate. In fact, you HAVE to speculate with speculative facts. As long as you speculate off of solid DD.
Dream: If more experienced investors were smart enough to avoid CVM, then they missed out on 500% gains this year. even at $1.30, CVM is up over four times its amount at the beginning of the year. I'm glad the more experienced investors were able to avoid those gains, if that truly is the case.
VFC
Man, you take a bitter pill or what? Have you ever smiled?
www.ncbi.nlm.nih.gov/p...
Goel N, Zimmerman DH, Rosenthal KS.
Northeastern Ohio Universities College of Medicine, 4209 SR 44, Rootstown, OH 44272, USA. ngoel@neoucom.edu <ngoel@neoucom.edu>
The Ligand Epitope Antigen Presentation System (L.E.A.P.S.) approach to vaccine development allowed construction of immunogens from defined T cell epitopes from herpes simplex virus (HSV) proteins that conferred protection against lethal challenge by the virus. This technology utilizes specific peptides which bind to CD4, CD8 or other proteins on the surface of T cells (T cell binding ligand (TCBL)), macrophage and dendritic cells (immune cell binding ligand (ICBL)) to promote the immunogenicity of an epitope, activate T cell and other protective responses, and direct the immune response to either a Th1 or a Th2 type of response. The J TCBL/ICBL is a peptide from beta-2-microglobulin which binds to the CD8 protein and promotes Th1 responses and the G TCBL/ICBL is a peptide from the beta chain of MHC II molecules that binds to the CD4 protein and promotes Th2 responses. Epitopes from the ICP27 (H1, H2), glycoprotein B (gB) and glycoprotein D (gD) proteins of HSV-1 were attached to either the J TCBL/ICBL or the G TCBL/ICBL. The JH1, JH2, JgB and JgD vaccines elicited DTH responses without antibody but conferred protection upon lethal challenge. Th1 related antibody was produced after challenge of the JgB and JgD immunized mice. Immunization with the GH1, GgB or GgD vaccines did not yield protection. The GgB and GgD produced Th2 related antibodies upon virus challenge. Initiation of the immune response by the JgD vaccine was dependent on functional CD4, CD8 expressing cells and interferon gamma and delivery of protection was dependent upon CD4 and interferon gamma. The L.E.A.P.S. HSV vaccines appear to elicit the appropriate immune responses for protection and further work is being performed to develop the JgD vaccine for human use.
make CVM look real bad because they know many follow "bad
stories" and then run for the Hilllllls.
I thank everybody who can not research and read betwen the
lines, so I was able to buy CVM at $ 1.32 and for sure wait
for $ 3.- and a lot more in the future .
Enjoy your writings and appreciate your research
Over at The Street amongst all the tumultuous writings on CVM, there is a comment by the writer: Turkeys Cant Fly.
On their post they state:
"CEL-SCI had outstanding convertible notes, options and warrants which as of November 30, 2008 could potentially allow the holders to acquire up to approximately 174,100,000 additional shares of its common stock. Until the options and warrants expire, or the convertible notes are paid, or the options or warrants expire, the holders will have an opportunity to profit from any increase in the market price of CEL-SCI's common stock without assuming the risks of ownership. Holders of convertible notes, options and warrants may convert or exercise these securities at a time when CEL-SCI could obtain additional capital on terms more favorable than those provided by the options. The conversion of the notes or the exercise of the options and warrants will dilute the voting interest..."
Can you elaborate on this at all? or is this a false inaccurate statement.
Thank you for your efforts
Richard Hamilton
I read Adam's latest slam. My question to you, CVM and BioReports is: If the FDA gives a biotech a no-holds-bared ticket to test the whiteblood cells it stands to reason their trials would have 10,000 or more samples to test by now. If anybody reads the paper or watches the news they would know that in Texas and Tenn. alone they would get that many. Just how many years through normal FDA years would it take otherwise to collect that many samples? Then knowing that cells in lab situations only last so long it appears in a month or so they would have more than enough evidence to go to the next with the FDA. Actual use on patients could be only a couple months away. At that time there would be 100,000 in the US alone. Normally how years would it take a biotech to 100,000 patients in a trial? Then knowing their manufacturing plant is about to open makes me wonder if the FDA already knows what the results would be and just wants these test and trials for the record. CVM's product could be on the market by the first of the year just before the major part of the swine flu is to hit. What do you think?
I've worked with the FDA and obtained two 510k's for simple medical devices several years ago. Unless things have changed, they aren't going to chat with anyone except the principal submittor about the technology/formulas/pa... involved.